A novel peptide‐based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies
Alzheimer's & Dementia · 2024-11 · 20 (11) · 7788-7804
DOI: 10.1002/alz.14246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 03.10.2024. Verfasst von Anthony Aggidis und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of Southampton, Southampton, UK. Hauptthemen laut MEDLINE: tau Proteins, Tauopathies, Alzheimer Disease. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION As aggregation underpins Tau toxicity, aggregation inhibitor peptides may have disease‐modifying potential. They are therefore currently being designed and target either the 306 VQIVYK 311 aggregation‐promoting hotspot found in all Tau isoforms or the 275 VQIINK 280 aggregation‐promoting hotspot found in 4R isoforms. However, for any Tau aggregation inhibitor to potentially be clinically relevant for other tauopathies, it should target both hotspots to suppress aggregation of Tau isoforms, be stable, cross the blood‐brain barrier, and rescue aggregation‐dependent Tau phenotypes in vivo. METHODS We developed a retro‐inverso, stable D‐amino peptide, RI‐AG03 [Ac‐rrrrrrrrGpkyk(ac)iqvGr‐NH2], based on the 306 VQIVYK 311 hotspots which exhibit these disease‐relevant attributes. RESULTS Unlike other aggregation inhibitors, RI‐AG03 effectively suppresses aggregation of multiple Tau species containing both hotspots in vitro and in vivo, is non‐toxic, and suppresses aggregation‐dependent neurodegenerative and behavioral phenotypes. DISCUSSION RI‐AG03 therefore meets many clinically relevant requirements for an anti‐aggregation Tau therapeutic and should be explored further for its disease‐modifying potential for Tauopathies. Highlights Our manuscript describes the development of a novel peptide inhibitor of Tau aggregation, a retro‐inverso, stable D‐amino peptide called RI‐AG03 that displays many clinically relevant attributes. We show its efficacy in preventing Tau aggregation in both in vitro and in vivo experimental models while being non‐toxic to cells. RI‐AG03 also rescues a biosensor cell line that stably expresses Tau repeat domains with the P301S mutation fused to Cer/Clo and rescues aggregation‐dependent phenotypes in vivo, suppressing neurodegeneration and extending lifespan. Collectively our data describe several properties and attributes of RI‐AG03 that make it a promising disease‐modifying candidate to explore for reducing pathogenic Tau aggregation in Tauopathies such as Alzheimer's disease. Given the real interest in reducing Tau aggregation and the potential clinical benefit of using such agents in clinical practice, RI‐AG03 should be investigated further for the treatment of Tauopathies after validation in mammalian models. Tau aggregation inhibitors are the obvious first choice as Tau‐based therapies as much of Tau‐mediated toxicity is aggregation dependent. Indeed, there are many research efforts focusing on this therapeutic strategy with aggregation inhibitors being designed against one of the two aggregation‐promoting hotspots of the Tau protein. To our knowledge, RI‐AG03 is the only peptide aggregation inhibitor that inhibits aggregation of Tau by targeting both aggregation‐promoting hotspot motifs simultaneously. As such, we believe that our study will have a significant impact on drug discovery efforts in this arena.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, University of Southampton, Southampton, UK.
- Division of Biomedical and Life Sciences, University of Lancaster, Lancaster, UK.
- Department of Science and Technology, Nottingham Trent University, Nottingham, UK.
- Department of Chemistry, University of Lancaster, Lancaster University, Lancaster, UK.
- Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
- Center for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
ORCID-Profile: Anthony Aggidis, George Devitt, Shreyasi Chatterjee, David Townsend, Nigel J Fullwood, Eva Ruiz Ortega, Airi Tarutani, Philip Williamson, Ayde Mendoza-Oliva, Marc I Diamond, Amritpal Mudher, David Allsop
Zitieren
APA
Aggidis, A., Devitt, G., Zhang, Y., Chatterjee, S., Townsend, D., Fullwood, N. J., Ortega, E. R., Tarutani, A., Hasegawa, M., Cooper, A., Williamson, P., Mendoza-Oliva, A., Diamond, M. I., Mudher, A., & Allsop, D. (2024). A novel peptide‐based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimer's & Dementia, 20(11), 7788-7804. https://doi.org/10.1002/alz.14246
Vancouver
Aggidis A, Devitt G, Zhang Y, Chatterjee S, Townsend D, Fullwood NJ, et al. A novel peptide‐based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimer's & Dementia. 2024;20(11):7788-7804. doi:10.1002/alz.14246
BibTeX
@article{Aggidis2024,
author = {Aggidis, Anthony and Devitt, George and Zhang, Yongrui and Chatterjee, Shreyasi and Townsend, David and Fullwood, Nigel J and Ortega, Eva Ruiz and Tarutani, Airi and Hasegawa, Masato and Cooper, Amber and Williamson, Philip and Mendoza-Oliva, Ayde and Diamond, Marc I and Mudher, Amritpal and Allsop, David},
title = {A novel peptide‐based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {11},
pages = {7788--7804},
doi = {10.1002/alz.14246}
}
EUVIMED